Laboratory of Precision NanoMedicine, Dept. of Cell Research & Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv 69978, Israel; Dept. of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv 69978, Israel; Center for Nanoscience and Nanotechnology, Tel Aviv 69978, Israel; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel.
Laboratory of Precision NanoMedicine, Dept. of Cell Research & Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv 69978, Israel; Dept. of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv 69978, Israel; Center for Nanoscience and Nanotechnology, Tel Aviv 69978, Israel; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel.
Semin Immunol. 2017 Dec;34:68-77. doi: 10.1016/j.smim.2017.08.015. Epub 2017 Sep 7.
mRNA molecules hold tremendous potential as a tool for gene therapy of a wide range of diseases. However, the main hurdle in implementation of mRNA for therapeutics, the systemic delivery of mRNA molecules to target cells, remains a challenge. A feasible solution for this challenge relies in the rapidly evolving field of nucleic acid-loaded nanocarriers and specifically in the established family of lipid-based nanoparticles (LNPs). Herein, we will discuss the main factors, which determine the fate of modified mRNA (mmRNA)-loaded LNPs in-vivo, and will focus on their interactions with the innate immune system as a main consideration in the design of lipid-based mmRNA delivery platforms.
mRNA 分子作为治疗多种疾病的基因治疗工具具有巨大的潜力。然而,将 mRNA 分子递送到靶细胞的系统给药是实现 mRNA 治疗的主要障碍,仍然是一个挑战。这个挑战的可行解决方案依赖于核酸负载纳米载体的快速发展领域,特别是在脂质纳米颗粒(LNPs)的既定家族中。在此,我们将讨论决定修饰 mRNA(mmRNA)负载的 LNPs 在体内命运的主要因素,并将重点讨论它们与先天免疫系统的相互作用,作为设计基于脂质的 mmRNA 递药平台的主要考虑因素。